Clincal Trial Endpoints in Ovarian Cancer

August 23, 2013

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

The oncology community would like to see a gold standard of improved overall survival or at least a good way to measure clinical benefit, Aghajanian says. Patients with ovarian cancer live for a long time, receive multiple lines of therapy, and often cross over, in a sense, to receive therapies in the same class.

These factors make it difficult to measure overall survival.

Clinical Pearls

  • The oncology community is still developing a good way to measure clinical benefit in ovarian cancer
  • Creating a gold standard endpoint for ovarian cancer is difficult due to patient parameters